HKBU scientists develop technique to eliminate drug side effects19 May 2020
The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.
Scientists from Hong Kong Baptist University (HKBU) have developed a novel technique that can produce pure therapeutic drugs without the associated side effects.
The approach, which uses a nanostructure fabrication device, can manipulate the chirality of drug molecules by controlling the direction a substrate is rotated within the device, thus eliminating the possible side effects that can arise when people take drugs containing molecules with the incorrect chirality.
Published Nature Chemistry, the research findings pave the way towards the mass production of purer, cheaper and safer drugs that can be made in a scalable and more environmentally-friendly way.
Many chemical molecules have two configurations, or chiral versions, that are mirror images of each other. While sharing the same molecular formula, the two chiral versions have different arrangements of their constituent atoms in space. The two versions of the molecules are characterized by left-handed and right-handed chiral configurations like human hands. Molecules with "left-handed" and "right-handed" chirality can have totally different biochemical effects.
More than half of the therapeutic drugs are made up of equal amounts of left-handed and right-handed chiral molecules; one can cure specific diseases, but the other may have adverse effects. Separating and producing molecules with only the chiral arrangement responsible for the therapeutic effects can help to produce drugs with improved safety and efficacy.
Existing technologies for producing single-enantiomer drugs are composed of complicated procedures are expensive and environmentally unfriendly.
Dr Jeffery Huang Zhifeng, Associate Professor in the Department of Physics at HKBU, and his research team devised a novel approach to manipulating molecular chirality through macro-scale control in collaboration with Sichuan University, Guangxi Medical University and the Southern University of Science and Technology.
"Our success in manipulating molecular chirality through macroscopic engineering allows the convenient synthesis of drugs in single-enantiomer forms with only left- or right-handedness. Hence, it will help get rid of the adverse, sometimes fatal, side effects of many therapeutic drugs," said Dr Huang.
The use of chiral ligands in the conventional method of asymmetric synthesis is inevitable, and it may cause pollution to enter the environment. In this novel approach, however, the metal nanohelices can be used repeatedly to produce single-enantiomer drugs without the use of chiral ligands. As a result, it paves the way towards the mass production of affordable therapeutic drugs that are made in a scalable manner with recyclable materials.
Ajinomoto introduces fast track platform for drug product manufacturing
30 Jun 2020
AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.Read more
Piramal acquires solid oral dosage drug product facility from G&W Laboratories
22 Jun 2020
The site can also produce liquids, creams, and ointments, further expanding the CDMO's portfolio.Read more
Catalent and ViralClear Pharmaceuticals partner on potential COVID-19 treatment
22 Jun 2020
The CDMO will work on developing a solution and a solid oral dosage form of ViralClear's merimepodib.Read more
Sanofi to build EUR 490 million vaccine production facility in France
16 Jun 2020
The French pharma company will also invest EUR 120 million to create a new research center at Marcy-l'Etoile dedicated to vaccinesRead more
Vektor Pharma finalizes formula for novel transdermal drug delivery system to treat Parkinson's
8 Jun 2020
Optimizing the dosage form's efficiency reduces the amount of drug required in each patch.Read more
Emergent bags $628 million "landmark" CDMO deal to produce COVID-19 vaccine candidates
2 Jun 2020
The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.Read more
Changes needed to prevent controversial pay-for-delay pharma deals
26 May 2020
Researchers endorse a switch from the current first-filer system in the US to a system that instead rewards the first successful challenger.Read more
SeraNova and Carna Biosciences to develop oral formulation of a new active ingredient
26 May 2020
SeraNovo enters into a second license agreement with Carna Biosciences for development of oral formulation of Carna’s kinase inhibitor.Read more
AbCellera and Lilly seal multi-year antibody discovery collaboration
25 May 2020
AbCellera, will use its antibody drug discovery platform to identify antibodies against up to nine targets.Read more
HKBU invents nanostructure that stimulates growth of stem cells for Parkinson's treatment
25 May 2020
The invention could pave the way for treatments to cure Parkinson's and Alzheimer's disease.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation